COMPASSION‑16 Phase 3 results indicate that adding cadonilimab, a bispecific PD‑1/CTLA‑4 inhibitor, to first‑line chemotherapy with or without bevacizumab improves clinical outcomes in advanced cervical cancer. Trial data released from the study demonstrated statistically meaningful gains in efficacy endpoints versus chemotherapy alone, positioning cadonilimab as a potential new backbone in this setting. Investigators stressed cadonilimab’s differentiated bispecific mechanism and its tolerability profile across cohorts. The study was presented at a major oncology forum and included global patient populations. If regulatory filings follow, the cadonilimab regimen could change first‑line standards for advanced cervical cancer, offering an immunotherapy option for patients historically underserved by checkpoint monotherapy approaches.